INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pennsylvania, July 29, 2020 /PRNewswire-AsiaNet/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).
...
Authors: LATEST ASIANET NEWS RELEASES